Evidence map›Paper›PMID 34095345›Full record

ArticleMolecular therapy. Methods & clinical development2021

Induced dendritic cells co-expressing GM-CSF/IFN-α/tWT1 priming T and B cells and automated manufacturing to boost GvL.

Julia K Bialek-Waldmann, Sabine Domning, Ruth Esser, Wolfgang Glienke, Mira Mertens, Krasimira Aleksandrova, Lubomir Arseniev, Suresh Kumar, Andreas Schneider, Johannes Koenig and 18 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 4 institutions in 2 countries.

Julia K Bialek-WaldmannDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Sabine DomningMolecular Medicine Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, Kings College London, London, UK.
Ruth EsserInstitute of Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany.
Wolfgang GlienkeInstitute of Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany.
Mira MertensInstitute of Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany.
Krasimira AleksandrovaInstitute of Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany.
Lubomir ArsenievInstitute of Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany.
Suresh KumarDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Andreas SchneiderDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Johannes KoenigDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Sebastian J TheobaldDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Hsin-Chieh TsayLaboratory of Regenerative Immune Therapies Applied, REBIRTH-Research Center for Translational Regenerative Medicine, Hannover Medical School, 30625 Hannover, Germany.
Angela D A CorneliusLaboratory of Regenerative Immune Therapies Applied, REBIRTH-Research Center for Translational Regenerative Medicine, Hannover Medical School, 30625 Hannover, Germany.
Agnes BonifaciusInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Britta Eiz-VesperInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Constanca FigueiredoInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Dirk SchaudienFraunhofer Institute for Toxicology and Experimental Medicine, 30625 Hannover, Germany.
Steven R TalbotInstitute for Laboratory Animal Science, Hannover Medical School, 30625 Hannover, Germany.
Andre BleichInstitute for Laboratory Animal Science, Hannover Medical School, 30625 Hannover, Germany.
Loukia M SpineliDepartment of Obstetrics, Gynecology and Reproductive Medicine, Hannover Medical School, 30625 Hannover, Germany.
Constantin von KaisenbergDepartment of Obstetrics, Gynecology and Reproductive Medicine, Hannover Medical School, 30625 Hannover, Germany.
Caren ClarkMiltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Rainer BlasczykInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, 30625 Hannover, Germany.
Michael HeuserDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Arnold GanserDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Ulrike KöhlInstitute of Cellular Therapeutics, Hannover Medical School, 30625 Hannover, Germany.
Farzin FarzanehMolecular Medicine Group, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, Kings College London, London, UK.
Renata StripeckeDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Medizinische Hochschule Hannover · DEKing's College London · GBFraunhofer Institute for Toxicology and Experimental Medicine · DEMiltenyi Biotec (Germany) · DE

Funding

Biotechnology and Biological Sciences Research Council BB/D014301/1Biotechnology and Biological Sciences Research Council BB/E005896/1
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) patients with minimal residual disease and receiving allogeneic hematopoietic stem cell transplantation (HCT) have poor survival. Adoptive administration of dendritic cells (DCs) presenting the Wilms tumor protein 1 (WT1) leukemia-associated antigen can potentially stimulate

Indexed as

automateddendritic cellsGMPgraft-versus-leukemiaimmunetherapylentiviral vectorsleukemiastem cell transplantationWT1

Identifiers

PMID34095345
PMCPMC8142053
OpenAlexW3153268370

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.